Drug resistance in malaria

British Medical Bulletin

Volumn 54, Issue 3, 1998, Pages 703-715

  White, N J ^a,b,c  

^a CHO QUAN HOSPITAL   (Viet Nam)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; AMOPYROQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ATOVAQUONE; BIGUANIDE DERIVATIVE; CHLORAMPHENICOL; CHLOROQUINE; CHLORPROGUANIL; CLINDAMYCIN; ERYTHROMYCIN; HALOFANTRINE; MEFLOQUINE; PROGUANIL; PYRIMETHAMINE; PYRONARIDINE; QUININE; RIFAMPICIN; SULFADOXINE;

AFRICA; AGRANULOCYTOSIS; CARDIOTOXICITY; DRUG MECHANISM; DRUG USE; HUMAN; MALARIA; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIORITY JOURNAL; REVIEW; SOUTH AMERICA;

EID: 0031752556     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.bmb.a011721     Document Type: Review

References (56)

1. Bjorkman A, Phillips-Howard PA. The epidemiology of drug-resistant malaria. Trans R Soc Trop Med Hyg 1990; 84: 177-80
2. White NJ. Antimalarial drug resistance: the pace quickens. J Antimicrob Chemother 1992; 30: 571-85
3. Foote SJ, Cowman AF. The mode of action and the mechanism of resistance to antimalarial drugs. Acta Tropica 1994; 56: 157-71
4. Peterson DS, Di Santi SM, Povoa M. Calvosa VS, do Rosario VE, Wellems TE. Prevalence of the dihydrofolate reductase Asn-108 mutation as the basis for pyrimethamine-resistant falciparum malaria in the Brazilian Amazon. Am J Trop Med Hyg 1991, 45: 492-7
5. Foote SJ, Galatis D, Cowman AF. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodiuum falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc Natl Acad Sci USA 1990; 87: 3014-7
6. Peterson DS, Milhous WK, Wellems TE. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc Natl Acad Sci USA 1990; 87: 3018-22
7. Peterson DS, Walliker D, Wellems TE. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA 1988: 85: 9114-8
8. Thaithong S, Chan SW, Songsomboon S et al. Pyrimethamine resistant mutations in Plasmodium falciparum. Mol Biochem Parasitol 1992; 52: 149-57
9. Field JW, Edeson JFB. Paludrine resistant falciparum malaria. Trans R Soc Trop Med Hyg 1949; 43: 233-6
10. Onyiorah E, van Hensbroek MB, Jah MS, Greenwood B. Early clinical failures after pyrimethamine-sulfadoxine treatment of uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 1996; 90: 307-8
11. Young MD, Moore DV. Chloroquine resistance in Plasmodium falciparum. Am J Trop Med Hyg 1961; 10: 317-20
12. Burgess RW, Young MD. The development of resistance by Plasmodium falciparum. Bull World Health Organ 1959; 20: 37-46
13. Bloland PB, Lackritz EM, Kazembe PN, Were JB, Steketee R, Campbell CC. Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J Infect Dis 1993, 167: 932-7
14. Ridley RG. Haemozoin formation in malaria parasites: is there a haem polymerase? Trends Microbiol 1996; 4: 253-4
15. Slater AF. Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum. Pharmacol Ther 1993; 57: 203-35
16. van Es HH, Karcz S, Chu F et al. Expression of the plasmodial pfmdr1 gene in mammalian cells is associated with increased susceptibility to chloroquine. Mol Cell Biol 1994; 14: 2419-28
17. Cowman AF, Galatis D, Thompson JK. Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc Natl Acad Sci USA 1994; 91: 1143-7
18. Foote SJ, Thompson JK, Cowman AF, Kemp DJ. Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum. Cell 1989; 57: 921-30
19. Wilson CM, Volkman SK, Thaithong S et al. Amplification of pfmdr1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand. Mol Biochem Parasitol 1993; 57: 151-60
20. Wellems TE, Walker-Jonah A, Panton LJ. Genetic mapping of the chloroquine-resistant locus on Plasmodium falciparum chromosome 7. Proc Natl Acad Sci USA 1991; 88: 3382-6
21. Martin SK, Oduola AMJ, Milhous WK. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science 1987; 235: 899-901
22. Bjorkman A, Willcox M, Kihamia CM et al. Field study of cyproheptadine/chloroquine synergism in falciparum malaria [letter]. Lancet 1990; 336: 59-60
23. Murphy GS, Basri H, Purnomo M et al. Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet 1993; 341: 96-100
24. Rieckmann KH, Davis DR, Hutton DC. Plasmodium vivax resistance to chloroquine. Lancet 1989; ii: 1183-4
25. Spencer HC, Oloo AJ, Watkins WW, Sixsmith DG, Churchill FC, Koech DK. Amodiaquine more effective than chloroquine against Plasmodium falciparum malaria on Kenya coast [letter]. Lancet 1984; i: 956-7
26. Hatten CS, Peto TEA, Bunch C, Pasvol G, Russel SJ, Singer CR. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet 1986; i: 411-4
27. Looareesuwan S, Kyle DE, Viravan C, Vanijanonta S, Wilairatana P, Wernsdorfer WH. Clinical Study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand. Am J Trop Med Hyg 1996; 54: 205-9
28. Harinasuta T, Bunnag D, Lasserre R, Leimer R, Vinijanont S. Trials of mefloquine in vivax and of mefloquine plus 'fansidar' in falciparum malaria. Lancet 1985; i: 885-8
29. Wongsrichanalai C, Webster HK, Wimonwattrawatee T et al. Emergence of multidrug-resistant Plasmodium falciparum in Thailand: in vitro tracking. Am J Trop Med Hyg 1992; 47: 112-6
30. Nosten F, ter Kuile F, Chongsuphajaisiddhi T et al. Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet 1991; 337: 1140-3
31. ter Kuile F, Nosten F, Thieren M et al. High dose mefloquine in the treatment of multidrug resistant falciparum malaria. J Infect Dis 1992; 166: 1393-400
32. Nosten F, Luxemburger C, ter Kuile F et al. Treatment of multi-drug resistant P. falciparum malaria with 3-day artesunate-rnefloquine combination. J Infect Dis 1994; 170: 971-7
33. Fontanet AL, Johnston DB, Walker AM et al. High prevalence of mefloquine-resistant falciparum malaria in eastern Thailand. Bull World Health Organ 1993; 71: 377-83
34. ter Kuile FO, Dolan G, Nosten F et al. Halofantrine versus mefloquine in the treatment of multi-drug resistant falciparum malaria. Lancet 1993; 341: 1044-9
35. Nosten F, ter Kuile FO, Luxemburger C et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet 1993; 341: 1054-6
36. Looareesuwan S, Wilairatana P, Vanijanonta S, Kyle D, Webster K. Efficacy of quinine-tetracycline for acute uncomplicated falciparum malaria in Thailand [letter]. Lancet 1992; 339: 369
37. Watt G, Loesuttivibool L, Shanks GD et al. Quinine with tetracycline for the treatment of drug-resistant falciparum malaria in Thailand. Am J Trop Med Hyg 1992; 47: 108-11
38. Meek SR, Doberstyn EB, Gauzere BA, Thanapanich C, Nordlander E, Phuphaisan S. Treatment of falciparum malaria with quinine and tetracycline or combined mefloquine/ sulfadoxine/ pyrimethamine on the Thai-Kampuchean border. Am J Trop Med Hyg 1986, 35: 246-50
39. Kremsner PG, Winkler S, Brandts C, Graninger W, Bienzle U. Curing of chloroquine-resistant malaria with clindamycin. Am J Trop Med Hyg 1993; 49: 650-4
40. Kremsner PG, Zotter GM, Feldmeier H, Graninger W, Westerman RL, Rocha RM. Clindamycin treatment of falciparum malaria in Brazil. J Antimicrob Chemother 1989; 23: 275-81
41. Hudson AT, Dickins M, Ginger CD et al. 566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients. Drugs Exp Clin Res 1991; 17: 427-35
42. Canfield CJ, Pudney M, Gutteridge WE. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp Parasitol 1995; 80: 373-81
43. Hien TT, White NJ. Qinghaosu. Lancet 1993, 341: 603-8
44. Meshnick SR. The mode of action of antimalarial endoperoxides. Trans R Soc Trop Med Hyg 1994, 88 (Suppl. 1):31-2
45. Foster S. Economic prospects for a new antimalarial drug. Trans R Soc Trop Med Hyg 1994, 88 (Suppl. 1): 55-6
46. ter Kuile FO, Nosten F, Luxemburger C et al. Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. Bull WHO 1995; 73:631-42
47. Mai NTH, Day NPJ, Chuong LV et al. Post malaria neurological syndrome. Lancet 1998; In press
48. Price RN, Nosten F, Luxemburger C et al. The effects of artemisinin derivatives on malaria transmissibility. Lancet 1996; 347: 1654-8
49. Brewer TG, Grate SJ, Peggins JO et al. Fatal neurotoxicity of arteether and artemether. Am J Trop Med Hyg 1994; 51: 251-9
50. Murphy S, English M, Waruiru C et al. An open randomized trial of artemether versus quinine in the treatment of cerebral malaria in African children. Trans R Soc Trop Med Hyg 1996; 90: 298-301
51. van Hensbroek MB, Onyiorah E, Jaffar S et al. A controlled trial of artemether or quinine in children with cerebral malaria. N Engl J Med 1996; 335: 69-75
52. Hien TT, Day NPJ, Phu NH et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 1996; 335: 76-83
53. Lipstitch M, Levin BR. The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother 1997; 41: 363-7
54. Watkins WM, Mosobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg 1993; 87: 75-8
55. White NJ. Assessment of the pharmacodynamic properties of the antimalarial drugs in vivo. Antimicrob Agents Chemother 1997; 41: 1413-22
56. White NJ. Preventing antimalarial drug resistance through combinations. Drug Res Updates 1998; 1: 3-9